Table 1.
Characteristic | No. (%) | Mean (SD) BCPT cognitive subscale score | P |
---|---|---|---|
Insomnia† | <.001 | ||
None (0–7) | 516 (48.13) | 0.65 (0.73) | |
Mild (8–14) | 343 (32.00) | 1.15 (0.90) | |
Moderate (15–21) | 167 (15.58) | 1.43 (0.84) | |
Severe (22–28) | 46 (4.29) | 2.24 (1.14) | |
Age, y | <.001 | ||
>65 | 363 (33.86) | 0.80 (0.84) | |
55–65 | 501 (46.74) | 1.02 (0.91) | |
<55 | 208 (19.40) | 1.32 (0.97) | |
Race | .58 | ||
White | 888 (82.84) | 0.99 (0.91) | |
Non-white | 184 (17.16) | 1.04 (0.94) | |
Education | .96 | ||
Did not graduate college | 434 (40.52) | 1.00 (0.94) | |
Graduated college | 637 (59.48) | 1.00 (0.90) | |
Body mass index, kg/m2 | .24 | ||
<25 | 416 (38.81) | 0.95 (0.89) | |
25–30 | 315 (29.38) | 1.00 (0.91) | |
>30 | 341 (31.81) | 1.06 (0.95) | |
Smoking | .36 | ||
Never smoked | 576 (53.83) | 1.03 (0.93) | |
Current or former smoker | 494 (46.17) | 0.97 (0.90) | |
Alcohol | .50 | ||
<1 drink daily | 885 (82.63) | 1.01 (0.92) | |
≥1 drink daily | 186 (17.37) | 0.96 (0.90) | |
Cancer stage | .42 | ||
0 and I | 551 (51.98) | 1.00 (0.95) | |
II | 370 (34.91) | 0.96 (0.85) | |
III | 139 (13.11) | 1.08 (0.94) | |
Years since cancer diagnoses | .97 | ||
<2 | 473 (44.12) | 1.01 (0.90) | |
2–5 y | 415 (38.71) | 1.00 (0.95) | |
>5 | 184 (17.16) | 0.99 (0.89) | |
Chemotherapy | .002 | ||
None | 515 (48.04) | 0.91 (0.90) | |
Chemotherapy without taxane | 103 (9.61) | 0.99 (0.83) | |
Taxane-based chemotherapy | 454 (42.35) | 1.11 (0.94) | |
Radiotherapy | .10 | ||
None | 304 (28.36) | 1.07 (0.97) | |
Yes | 768 (71.64) | 0.97 (0.89) | |
Surgery | .002 | ||
Lumpectomy | 620 (57.89) | 0.93 (0.89) | |
Mastectomy | 451 (42.11) | 1.10 (0.94) | |
Current aromatase inhibitors (AI) | 1.00 | ||
Anastrozole | 863 (80.88) | 1.00 (0.94) | |
Exemestane | 57 (5.34) | 1.00 (0.78) | |
Letrozole | 147 (13.78) | 1.00 (0.82) | |
Years of AI use | .27 | ||
>3 | 269 (25.09) | 0.94 (0.89) | |
1–3 | 546 (50.93) | 1.00 (0.93) | |
<1 | 257 (23.97) | 1.07 (0.91) | |
Anxiety | <.001 | ||
No (HADS <8) | 731 (68.77) | 0.78 (0.80) | |
Borderline (8–10) | 206 (19.38) | 1.31 (0.96) | |
Clinically abnormal (≥11) | 126 (11.85) | 1.79 (0.91) | |
Depression | <.001 | ||
No (HADS <8) | 933 (88.02) | 0.89 (0.83) | |
Borderline (8–10) | 92 (8.68) | 1.73 (0.94) | |
Clinically Abnormal (≥11) | 35 (3.30) | 2.22 (1.22) |
Variables associated with the primary outcome at P < .10 were included in the multivariable linear regression analyses (Table 2). AI = aromatase inhibitor; HADS = Hospital Anxiety and Depression Scale.
Insomnia Severity Index.